| Ytd | 4.09% | |
| 1y | -4.34% |
| Open | 1.65 | Prev Close | 1.65 | Low | 1.65 | High | 1.68 | Mkt Cap | 164.14M |
| Vol | 87.85K | Avg Vol | 2.00M | EPS | -1.19 | P/E | -1.39 | Forward P/E | -0.90 |
| Beta | 2.26 | Short Ratio | 4.55 | Inst. Own | 62.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 1.76 | 200-d Avg | 1.86 | 1yr Est | 12.50 |
CRBU News
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their se
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a lead
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, an
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advanci
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Trans
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longe
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precis
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety riv
Executives from Caribou Biosciences (NASDAQ: CRBU) outlined upcoming clinical, regulatory, and finan
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.28 per share versus the Zacks
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a lea
During Monday's trading, 1214 companies set new 52-week lows.